Most prominently, studies on RTD caused by SLC52A2/SLC52A3 mutations show that systemic delivery of AAV9-SLC52A2 in loss-of-function mouse models restores transporter expression, corrects spinal motor neuron energy deficits, reverses motor dysfunction, and extends survival. This evidence concerns the gene SLC52A3 and renal tubular dysgenesis of genetic origin.